UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(c)
Effective as of December 6, 2022, ARS Pharmaceuticals, Inc. (the “Company”) appointed Brian T. Dorsey, MSc, as Chief Operations Officer of the Company.
Mr. Dorsey, age 54, has served as the Company’s Senior Vice President of Operations and Project Management since October 2018. He has served in the pharmaceutical and biotechnology industries for more than 20 years providing high-level drug development, regulatory and QC/QA leadership of pharmaceutical candidates from early development through FDA approval. Mr. Dorsey is a founding partner at MagnaSci Ventures, a healthcare fund focused on investing in early-stage life science companies. He is a founder of numerous companies including Kalyra Pharmaceuticals and Septum Solutions. Prior to joining the Company, Mr. Dorsey was Chief Development Officer for Apricus BioSciences (Nasdaq: APRI) from December 2014 to October 2018. Mr. Dorsey has also held various senior management positions including Senior Vice President of Research and Development and Chief Compliance Officer of Pernix Therapeutics Holding; Senior Vice President of Technical Operations and Regulatory Affairs for Somaxon Pharmaceuticals; Head of Project Management, Medical Writing and Library Services at Maxim Pharmaceuticals; Head of Biopharmaceutical Project Management of Baxter Bioscience and Manager of Chemistry, Manufacturing, and Control for Chugai Biopharmaceuticals. Mr. Dorsey has held several positions within the Agouron/Warner Lambert/Pfizer organization and has lead development projects in the antiviral, oncology, and ophthalmology therapeutic areas. He serves on the board of directors for Forward Sciences, Forge Therapeutics and Blacksmith Medicines. Mr. Dorsey received his Master of Science in Executive Leadership and his B.A. in chemistry from the University of San Diego.
The Company and Mr. Dorsey entered into an Executive Employment Agreement effective as of October 1, 2018 (the “Dorsey Agreement”). Pursuant to the terms of the Dorsey Agreement, Mr. Dorsey is entitled to (i) an initial base salary of $100,000, which was subsequently increased to his current base salary of $319,800 and increased again to $410,000 in connection with his appointment as Chief Operations Officer, which was approved in December 2022 and (ii) an annual discretionary cash bonus of up to 40% of his then-current base salary, pro-rated in the case of a partial calendar year.
Mr. Dorsey will be eligible to participate in the Company’s Change in Control and Severance Benefit Plan (the “Severance Plan”). Under the Severance Plan, Mr. Dorsey will be eligible to receive certain severance benefits in the event of limited qualifying termination events. The Severance Plan was previously filed as Exhibit 10.14 to the Company’s Registration Statement on Form S-1 (No. 333-250009).
The foregoing description of the Dorsey Agreement is not complete and is qualified in its entirety by reference to the full text of the Dorsey Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
Exhibit |
Description | |
10.1 | Executive Employment Agreement, by and between the Company and Brian T. Dorsey, effective as of October 1, 2018. | |
104 | Cover Page of Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 9, 2022 | ARS Pharmaceuticals, Inc. | |||||
|
By: | /s/ Richard Lowenthal, M.S., MSEL | ||||
|
Name: | Richard Lowenthal, M.S., MSEL | ||||
|
Title: | President and Chief Executive Officer |
Exhibit 10.1
ARS PHARMACEUTICALS, INC.
EXECUTIVE EMPLOYMENT AGREEMENT
for
BRIAN T. DORSEY
This Executive Employment Agreement (this Agreement) is made and entered into effective as of October 1, 2018 (the Effective Date), by and between Brian T. Dorsey (Executive) and ARS Pharmaceuticals, Inc. (the Company).
1. Employment by the Company.
1.1 Position. Executive shall serve as the Companys Senior Vice President of Operations and Project Management (SVP), reporting to the Companys Chief Executive Officer. During the term of Executives employment with the Company, Executive will devote Executives best efforts, on a part-time (approximately 35%) basis, to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities all in conformity with the Companys policies applicable to senior executives and general employment policies. Company agrees and acknowledges that the amount of time devoted to Executives duties as a part-time employee may fluctuate in any given period of time, but is intended to reflect approximately 35% of Executives time over the course of a twelve month period. Executives employment will begin on or around October 1, 2018, at a date mutually agreeable to Executive and the Company and, the actual first day of employment shall be referred to as Executives Start Date.
1.2 Duties and Location. Executive shall perform such duties as are customarily associated with the position and such other duties as are assigned to Executive by the Companys Chief Executive Officer or the Companys Board of Directors (the Board). Executives primary office location shall be the Companys office located in San Diego, California, and Executive will travel as reasonably required by the Company for business purposes. Notwithstanding, Executive may perform his duties both in and outside the office, and during or outside of regular business hours, as may be convenient.
1.3 Policies and Procedures. The employment relationship between the parties shall be governed by the general employment policies and practices of the Company and applicable California law, except that when the terms of this Agreement differ from or are in conflict with the Companys general employment policies or practices, this Agreement shall control.
2. Compensation.
2.1 Base Salary. Executive shall receive a base salary at the annual rate of $100,000, less standard payroll deductions and withholdings and payable in accordance with the Companys regular payroll schedule. The Company will pay your salary semi-monthly.
1
2.2 Incentive Compensation. Subject to Board approval, the Company intends to establish an annual incentive compensation plan. Once established, the details of the annual incentive compensation plan, including the applicable terms and conditions of such plan and Executives eligibility to participate in such plan, will be provided to Executive.
2.3 Equity Grant. Subject to approval of the Board, the Company will grant to Executive an option (the Options) to purchase 120,000 shares of the Companys Common Stock pursuant to the Companys 2018 Equity Incentive Plan. The Options shall vest in equal monthly installments over the following three years commencing with the first monthly anniversary of your Start Date and the remainder vesting in 35 additional monthly installments.
3. Standard Company Benefits. Executive shall, in accordance with Company policy and the terms and conditions of the applicable Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to its executive officers and other employees from time to time. Any such benefits shall be subject to the terms and conditions of the governing benefit plans and policies and may be changed by the Company in its discretion. Currently, company benefits for healthcare and other insurance require employment at a 50% or greater level. Bonus and other incentive benefits are considered based on the percentage of time devoted to the company.
4. Expenses. The Company shall pay or reimburse Executive, on a monthly basis, for reasonable travel, entertainment, promotional and other expenses incurred by Executive in the performance of his business-related obligations under this Agreement (collectively Expenses). To be eligible for reimbursement of any Expenses under this Agreement, Executive must submit timely detailed expense reports, receipts or other satisfactory evidence of payment for appropriate review within 30 days of incurring such expense. The Company shall reimburse Executive promptly, but in no event later than thirty (30) days after Executive submits an expense report in accordance with the preceding sentence.
5. Confidential Information Obligations.
5.1 Confidential Information Agreement. As a condition of employment, and in consideration for the benefits provided for in this Agreement, Executive agrees to continue to abide by the Companys Employee Confidential Information and Inventions Assignment Agreement (the Confidential Information Agreement) that he previously executed. In addition, Executive agrees to abide by the Companys policies and procedures, as may be modified from time to time within the Companys discretion.
5.2 Third-Party Agreements and Information. Executive represents and warrants that Executives employment by the Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Executive will perform Executives duties to the Company without violating any such agreement. Executive represents and warrants that Executive does not possess confidential information arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Executives employment by the Company, except as expressly authorized by that third party. During Executives employment by the Company, Executive will use in the performance of Executives duties only information that is generally known and used by persons with training and experience comparable to Executives own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executives work for the Company.
2
6. Outside Activities and Non-Competition During Employment.
6.1 Outside Activities. Company agrees and acknowledges that Executive shall be a part-time employee of Company as set forth herein and shall, subject to the restrictions set forth in the Confidential Information Agreement and Section 6.2 hereof, be free to engage in other types of business or public activities (including, without limitation, independent consulting, part-time employment, and serving as a scientific advisor and/or member of or observer to a corporate board of directors).
6.2 Non-Competition During Employment. Throughout Executives employment with the Company, Executive will not, without the express written consent of the Board, directly or indirectly serve as an officer, employee, or independent consultant of or to any person or entity engaged in the business of drug development in the field of Nasal Products.
7. Termination of Employment
7.1 At-Will Employment. Executives employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause (as defined below) or advance notice.
7.2 Termination Without Cause or Resignation for Good Reason. In the event Executives employment with the Company is terminated by the Company without Cause (and other than as a result of Executives death or disability) or Executive resigns for Good Reason, such termination or resignation constitutes a separation from service (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a Separation from Service), and provided that Executive satisfies the Release Requirement in Section 8 below, and remains in compliance with the terms of this Agreement and the Confidential Information Agreement, the Company shall provide Executive with the following Severance Benefits:
7.2.1 Severance Payments. Following the initial twelve (12) month cliff period, severance pay in the form of continuation of Executives final base salary for a period of three (3) months following termination, subject to required payroll deductions and tax withholdings (the Severance Payments). Subject to Section 9 below, the Severance Payments shall be made on the Companys regular payroll schedule in effect following Executives termination date; provided, however that any such payments that are otherwise scheduled to be made prior to the Release Effective Date (as defined below) shall instead accrue and be made on the first administratively practicable payroll date following the Release Effective Date. For such purposes, Executives final base salary will be calculated prior to giving effect to any reduction in base salary that would give rise to Executives right to resign for Good Reason.
3
7.2.2 Health Care Continuation Coverage Payments.
(i) COBRA Premiums. If Executive timely elects continued coverage under COBRA, the Company will pay Executives COBRA premiums to continue Executives coverage (including coverage for Executives eligible dependents, if applicable) (COBRA Premiums) through the period starting on the termination date and ending three (3) months after the termination date (the COBRA Premium Period); provided, however, that the Companys provision of such COBRA Premium benefits will immediately cease if during the COBRA Premium Period Executive becomes eligible for group health insurance coverage through a new employer or Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employers group health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, Executive must immediately notify the Company of such event.
(ii) Special Cash Payments in Lieu of COBRA Premiums. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Executive or Executives dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Executive, on the first day of each calendar month following the termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for Executives eligible dependents), subject to applicable tax withholdings (such amount, the Special Cash Payment), for the remainder of the COBRA Premium Period. Executive may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums.
7.3 Termination for Cause; Resignation Without Good Reason; Death or Disability. Executive will not be eligible for, or entitled to any severance benefits, including (without limitation) the Severance Benefits listed in Section 7.2 above, if (i) the Company terminates Executives employment for Cause, (ii) Executive resigns Executives employment without Good Reason, or (iii) Executives employment terminates due to Executives death or disability. Furthermore, Executive will not be eligible for, or entitled to, any severance benefits listed in Section 7.2.1 or Section 7.2.3 above if Executives employment terminates for any reason prior to the first year anniversary of the Effective Date.
8. Conditions to Receipt of Severance Benefits. To be eligible for the Severance Benefits pursuant to Section 7.2 above, Executive must satisfy the following release requirement (the Release Requirement): return to the Company a signed and dated general release of all known and unknown claims in a termination agreement acceptable to the Company (the Release) within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following Executives termination date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective date of the Release, the Release Effective Date). No Severance Benefits will be provided hereunder prior to the Release Effective Date. Accordingly, if Executive refuses to sign and deliver to the Company an executed Release or signs and delivers to the Company the Release but exercises Executives right, if any, under applicable law to revoke the Release (or any portion thereof), then Executive will not be entitled to any severance, payment or benefit under this Agreement.
4
9. Section 409A. It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executives right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executives Separation from Service to be a specified employee for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be deferred compensation, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month and one day period measured from the date of Executives Separation from Service with the Company, (ii) the date of Executives death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 9 shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. If the Company determines that any severance benefits provided under this Agreement constitutes deferred compensation under Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective date of the Release will not be deemed to have occurred any earlier than the sixtieth (60th) date following the Separation From Service, regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for Executive to execute (and not revoke) the applicable Release spans two calendar years, payment of the applicable severance benefits shall not commence until the beginning of the second calendar year. To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A, amounts reimbursable to Executive under this Agreement shall be paid to Executive on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Executive) during any one year may not effect amounts reimbursable or provided in any subsequent year. The Company makes no representation that any or all of the payments described in this Agreement will be exempt from or comply with Code Section 409A and makes no undertaking to preclude Code Section 409A from applying to any such payment.
5
10. Definitions.
10.1 Cause. For the purposes of this Agreement, Cause means the occurrence of any one or more of the following: (i) Executives conviction of or plea of guilty or nolo contendere to any felony or any crime of moral turpitude; (ii) Executives continued failure or refusal to follow lawful instructions of the Board or lawful policies and regulations of the Company; (iii) Executives continued failure to faithfully and diligently perform the assigned duties of Executives employment with the Company; (iv) Executives violation of a fiduciary duty or duty or loyalty owed to the Company or its affiliates; (v) unprofessional, unethical, immoral or fraudulent conduct by Executive that materially discredits the Company or its affiliates, or is materially detrimental to the reputation, character and standing of the Company or its affiliates; or (vi) Executives material breach of this Agreement, the Confidential Information Agreement, or any written Company policies. An event described in Section 10.1(ii) through Section 10.1(vi) herein shall not be treated as Cause until after Executive has been given written notice of such event, failure, conduct or breach and Executive fails to cure such event, failure, conduct or breach within 30 calendar days from such written notice; provided, however, that such 30 calendar day cure period shall not be required if the event, failure, conduct or breach is incapable of being cured.
10.2 Good Reason. For purposes of this Agreement, Executive shall have Good Reason for resignation from employment with the Company if any of the following actions are taken by the Company without Executives prior written consent: (i) a material reduction in Executives base salary, unless pursuant to a salary reduction program applicable generally to the Companys senior executives; or (ii) a material reduction in Executives duties (including responsibilities and/or authorities), provided, however, that a change in job position (including a change in title) or reporting line shall not be deemed a material reduction in and of itself unless Executives new duties are materially reduced from the prior duties. In order for Executive to resign for Good Reason, each of the following requirements must be met: (iii) Executive must provide written notice to the Board within 30 calendar days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executives resignation, (iv) Executive must allow the Board at least 30 calendar days from receipt of such written notice to cure such event, (v) such event is not reasonably cured within such 30 calendar day period (the Cure Period), and (vi) Executive must resign from all positions Executive then holds with the Company and its affiliates not later than 30 calendar days after the expiration of the Cure Period.
11. Dispute Resolution. To ensure the rapid and economical resolution of disputes that may arise in connection with Executives employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Executives employment with the Company, or the termination of Executives employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in San Diego, California by JAMS, Inc. (JAMS) or its successors by a single arbitrator. Both Executive and the Company acknowledge that by agreeing to this arbitration procedure, they each waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. Any such arbitration proceeding will be governed by JAMS then applicable rules and procedures for employment disputes, which will be provided to Executive upon request. Questions of whether a claim is subject to arbitration under this Agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. In any such arbitration, the arbitrator shall: (i) have the authority to compel adequate discovery for the
6
resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision including the arbitrators essential findings and conclusions and a statement of the award. Executive and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or Executive from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrators fees and any other fees or costs unique to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. In the event of any such arbitration, the arbitrator shall (as opposed to may) award the prevailing party his or its costs of arbitration including but not limited to reasonable attorneys fees; arbitration forum and arbitrator fees; travel expenses; expert fees and such other usual and customary costs incurred in an arbitration.
12. General Provisions.
12.1 Notices. Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.
12.2 Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.
12.3 Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.
12.4 Complete Agreement. This Agreement, together with the Confidential Information Agreement, constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof and is the complete, final, and exclusive embodiment of the Companys and Executives agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes and replaces any other agreements or promises made to Executive by anyone concerning Executives employment terms, compensation or benefits, whether oral or written. It cannot be modified or amended except in a writing signed by a duly authorized officer of the Board, with the exception of those changes expressly reserved to the Companys discretion in this Agreement.
12.5 Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but both of which taken together will constitute one and the same Agreement.
7
12.6 Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.
12.7 Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of Executives duties hereunder and Executive may not assign any of Executives rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.
12.8 Tax Withholding. All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to this Agreement.
12.9 Choice of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.
[Signature Page Follows]
8
IN WITNESS WHEREOF, this Agreement shall be effective as of the Effective Date.
ARS PHARMACEUTICALS, INC. | ||
By: | /s/ Richard Lowenthal | |
Richard Lowenthal | ||
Chief Executive Officer | ||
EXECUTIVE | ||
/s/ Brian Dorsey | ||
Brian Dorsey |
[SIGNATURE PAGE TO EMPLOYMENT AGREEMENT]